Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,337,056
  • Shares Outstanding, K 155,320
  • Annual Sales, $ 903,370 K
  • Annual Income, $ -157,950 K
  • 36-Month Beta 1.72
  • Price/Sales 7.11
  • Price/Cash Flow 149.92
  • Price/Book 5.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.28
  • Number of Estimates 2
  • High Estimate -0.26
  • Low Estimate -0.31
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -211.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.68 +1.21%
on 09/20/18
45.16 -11.07%
on 10/08/18
+0.58 (+1.47%)
since 09/19/18
3-Month
38.23 +5.05%
on 09/17/18
46.98 -14.52%
on 08/31/18
-5.12 (-11.31%)
since 07/19/18
52-Week
38.23 +5.05%
on 09/17/18
71.22 -43.61%
on 02/16/18
-10.40 (-20.57%)
since 10/19/17

Most Recent Stories

More News
Alkermes Boasts Strong Portfolio and Impressive Pipeline

Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.

MRK : 72.35 (+0.19%)
LLY : 111.92 (-1.23%)
ALKS : 40.16 (-1.57%)
BIIB : 320.41 (-2.95%)
EBS or ALKS: Which Is the Better Value Stock Right Now?

EBS vs. ALKS: Which Stock Is the Better Value Option?

EBS : 60.74 (-1.56%)
ALKS : 40.16 (-1.57%)
Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress

Alkermes plc (Nasdaq: ALKS) today announced the presentation of 10 posters at the upcoming 31st Annual Psych Congress (Psych Congress) in Orlando, Oct. 25-28, 2018. Poster presentations will include clinical...

ALKS : 40.16 (-1.57%)
Alkermes to Host Conference Call to Discuss Third Quarter 2018 Financial Results

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET (1:30 p.m. BST) on Tuesday, Oct. 23, 2018, to discuss the company's third quarter 2018 financial results....

ALKS : 40.16 (-1.57%)
FDA Sets Action Date for Recro's Pain Management Candidate

The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.

CRSP : 36.04 (-3.12%)
AMGN : 201.80 (-0.45%)
ALKS : 40.16 (-1.57%)
REPH : 7.23 (+0.70%)
VistaGen Up on Fast Track Designation to Pain Candidate

VistaGen (VTGN) Fast Track designation for its pipeline candidate, AV-101, for treating neuropathic pain.

LGND : 187.52 (-4.84%)
CLBS : 4.56 (-1.94%)
ALKS : 40.16 (-1.57%)
VTGN : 2.20 (+4.27%)
Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA

FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.

AZN : 39.21 (+0.67%)
JNJ : 139.05 (-0.32%)
AGN : 189.53 (+0.34%)
ALKS : 40.16 (-1.57%)
Consolidated Research: 2018 Summary Expectations for Pan American Silver, Invesco, Diodes, INVESCO MORTGAGE CAPITAL INC, Alkermes plc, and Golar LNG Partners LP -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Pan American Silver Corp. (NASDAQ:PAAS),...

IVR : 14.77 (+0.07%)
PAAS : 15.50 (-0.06%)
DIOD : 29.32 (-1.54%)
GMLP : 14.07 (+0.43%)
IVZ : 21.98 (+3.39%)
ALKS : 40.16 (-1.57%)
Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?

Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.

ALKS : 40.16 (-1.57%)
Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo

Alkermes expands a phase I study to evaluate its immuno-oncology candidate, ALKS 4230, in combination with Keytruda in patients with advanced solid tumors.

LGND : 187.52 (-4.84%)
MRK : 72.35 (+0.19%)
ALKS : 40.16 (-1.57%)
BIIB : 320.41 (-2.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ALKS with:

Business Summary

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication...

See More

Key Turning Points

2nd Resistance Point 42.81
1st Resistance Point 41.49
Last Price 40.16
1st Support Level 39.34
2nd Support Level 38.51

See More

52-Week High 71.22
Fibonacci 61.8% 58.62
Fibonacci 50% 54.72
Fibonacci 38.2% 50.83
Last Price 40.16
52-Week Low 38.23

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar